This bulletin covers aspects of breast cancer, and should be of interest to multidisciplinary teams working in this area.
Sections can include:
· Combined Modality Therapies
· Drug Therapy
· Pathology, Staging, Polymorphisms & Biomarkers
· Prognosis, Survival & Risk Factors
· Radiotherapy & Imaging
· Supportive Care & Symptom Management
· Surgery
Many of the following articles are available online via the NHS Scotland Knowledge Network. Please use the links where provided and your ATHENS password. A complete list of available online journals and registration for ATHENS can be found at www.knowledge.scot.nhs.uk/
If the article you require is not available via the NHS Scotland Knowledge Network and you would like to request a print copy, please submit your request online at www.quest.scot.nhs.uk
This bulletin contains a selection of material gathered from a search of the evidence base, and is not intended to be comprehensive. Professional judgment should be exercised when appraising the material. The Library takes no responsibility for the wording, content and accuracy of the information supplied, which has been extracted in good faith from reputable sources. NHSGGC is not responsible for the content of external internet sites.
Compiled by:
Kirsty Coltart
Subject Librarian
Beatson West of Scotland Cancer Centre
0141 301 7285,
GENERAL
Brackstone M, Fletcher GG, Dayes IS, et al. (2015). Locoregional therapy of locally advanced breast cancer: a clinical practice guideline. Current Oncology 22,Suppl 1:S54-66.
de Glas NA, Kiderlen M, de Craen AJ, et al. (2015). Assessing treatment effects in older breast cancer patients: systematic review of observational research methods. Cancer treatment reviews 41,3:254-261.
Garcia C and Powell CB. (2015). A comprehensive approach to the identification and management of the BRCA patient. Obstetrical & gynecological survey 70,2:131-143.
Gradishar WJ, Anderson BO, Balassanian R, et al. (2015). Breast cancer version 2.2015. Journal of the National Comprehensive Cancer Network 13,4:448-475.
Kowalski C, Ferencz J, Brucker SY, et al. (2015). Quality of care in breast cancer centers: Results of benchmarking by the German Cancer Society and German Society for Breast Diseases. Breast 24,2:118-123.
Ribnikar D, Ribeiro JM, Pinto D, et al. (2015). Breast cancer under age 40: a different approach. Current Treatment Options in Oncology 16,4:334.
COMBINED MODALITY THERAPIES
Ataseven B, Lederer B, Blohmer JU, et al. (2015). Impact of multifocal or multicentric disease on surgery and locoregional, distant and overall survival of 6,134 breast cancer patients treated with neoadjuvant chemotherapy. Annals of Surgical Oncology 22,4:1118-1127.
Bartelink H, Maingon P, Poortmans P, et al. (2015). Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncology 16,1:47-56.
Esposito E, Anninga B, Harris S, et al. (2015). Intraoperative radiotherapy in early breast cancer. British Journal of Surgery 102,6:599-610.
Garg AK and Buchholz TA. (2015). Influence of neoadjuvant chemotherapy on radiotherapy for breast cancer. Annals of Surgical Oncology 22,5:1434-1440.
Hanna GG and Kirby AM. (2015). Intraoperative radiotherapy in early stage breast cancer: potential indications and evidence to date. British Journal of Radiology 88,1049:20140686.
Kunkler IH, Williams LJ, Jack WJ, et al. (2015). Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncology 16,3:266-273.
Rochlin DH, Jeong AR, Goldberg L, et al. (2015). Postmastectomy radiation therapy and immediate autologous breast reconstruction: integrating perspectives from surgical oncology, radiation oncology, and plastic and reconstructive surgery. Journal of surgical oncology 111,3:251-257.
DRUG & TARGETED THERAPY
Blok EJ, Derks MG, van der Hoeven JJ, et al. (2015). Extended adjuvant endocrine therapy in hormone-receptor positive early breast cancer: current and future evidence. Cancer treatment reviews 41,3:271-276.
Carbognin L, Sperduti I, Nortilli R, et al. (2015). Balancing activity and tolerability of neoadjuvant paclitaxel- and docetaxel-based chemotherapy for HER2-positive early stage breast cancer: sensitivity analysis of randomized trials. Cancer treatment reviews 41,3:262-270.
Cuzick J, Sestak I, Cawthorn S, et al. (2015). Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncology 16,1:67-75.
Eisen A, Fletcher GG, Gandhi S, et al. (2015). Optimal systemic therapy for early breast cancer in women: a clinical practice guideline. Current Oncology 22,Suppl 1:S67-81.
Fallowfield L, Osborne S, Langridge C, et al. (2015). Implications of subcutaneous or intravenous delivery of trastuzumab; further insight from patient interviews in the PrefHer study. Breast 24,2:166-170.
Finn RS, Crown JP, Lang I, et al. (2015). The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncology 16,1:25-35.
Francis PA, Regan MM, Fleming GF, et al. (2015). Adjuvant ovarian suppression in premenopausal breast cancer. New England Journal of Medicine 372,5:436-446.
Freedman OC, Fletcher GG, Gandhi S, et al. (2015). Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline. Current Oncology 22,Suppl 1:S95-S113.
Gandhi S, Fletcher GG, Eisen A, et al. (2015). Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline. Current Oncology 22,Suppl 1:S82-94.
Hicks M, Macrae ER, Abdel-Rasoul M, et al. (2015). Neoadjuvant Dual HER2-Targeted Therapy With Lapatinib and Trastuzumab Improves Pathologic Complete Response in Patients With Early Stage HER2-Positive Breast Cancer: A Meta-Analysis of Randomized Prospective Clinical Trials. Oncologist 20,4:337-343.
Hu XC, Zhang J, Xu BH, et al. (2015). Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncology 16,4:436-446.
Joy AA, Ghosh M, Fernandes R, et al. (2015). Systemic treatment approaches in her2-negative advanced breast cancer-guidance on the guidelines. Current Oncology 22,Suppl 1:S29-42.
Kaufman PA, Awada A, Twelves C, et al. (2015). Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. Journal of Clinical Oncology 33,6:594-601.
Martin M, Loibl S, von Minckwitz G, et al. (2015). Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy As First-Line Treatment for Advanced Breast Cancer: The Letrozole/Fulvestrant and Avastin (LEA) Study. Journal of Clinical Oncology 33,9:1045-1052.
Martin M, Martinez N, Ramos M, et al. (2015). Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM/2009-05): a randomized, noninferiority phase II trial with a pharmacogenetic analysis. Oncologist 20,2:111-112.
Mates M, Fletcher GG, Freedman OC, et al. (2015). Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline. Current Oncology 22,Suppl 1:S114-22.
Moore HC, Unger JM, Phillips KA, et al. (2015). Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. New England Journal of Medicine 372,10:923-932.
Perrone F, Nuzzo F, Di Rella F, et al. (2015). Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Annals of Oncology 26,4:675-682.
Swain SM, Baselga J, Kim SB, et al. (2015). Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. New England Journal of Medicine 372,8:724-734.
Zhu X and Verma S. (2015). Targeted therapy in her2-positive metastatic breast cancer: a review of the literature. Current Oncology 22,Suppl 1:S19-28.
PATHOLOGY, STAGING, POLYMORPHISMS, BIOMARKERS
Abdel-Fatah TM, Middleton FK, Arora A, et al. (2015). Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer. Molecular Oncology 9,3:569-585.
Beije N, Jager A and Sleijfer S. (2015). Circulating tumor cell enumeration by the CellSearch system: the clinician's guide to breast cancer treatment? Cancer treatment reviews 41,2:144-150.
Fitzal F, Filipits M, Rudas M, et al. (2015). The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial. British journal of cancer 112,8:1405-1410.
Guo Q, Schmidt MK, Kraft P, et al. (2015). Identification of novel genetic markers of breast cancer survival. Journal of the National Cancer Institute 107,5:
Pogue-Geile KL, Song N, Jeong JH, et al. (2015). Intrinsic Subtypes, PIK3CA Mutation, and the Degree of Benefit From Adjuvant Trastuzumab in the NSABP B-31 Trial. Journal of Clinical Oncology 33,12:1340-1347.
PROGNOSIS, SURVIVAL, RISK FACTORS
Bantema-Joppe EJ, de Bock GH, Woltman-van Iersel M, et al. (2015). The impact of age on changes in quality of life among breast cancer survivors treated with breast-conserving surgery and radiotherapy. British journal of cancer 112,4:636-643.
Fei F, Messina C, Slaets L, et al. (2015). Tumour size is the only predictive factor of distant recurrence after pathological complete response to neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancers: a sub-study of EORTC 10994/BIG 1-00 phase III trial. European journal of cancer 51,3:301-309.
Layfield DM, Mohamud M, Odofin O, et al. (2015). Tumour grade on core biopsy and evidence of axillary involvement on ultrasound predicts response in elderly co-morbid patients treated with primary hormone therapy for oestrogen receptor positive breast carcinoma. Surgeon Journal of the Royal Colleges of Surgeons of Edinburgh & Ireland 13,2:61-68.
Mavaddat N, Pharoah PD, Michailidou K, et al. (2015). Prediction of breast cancer risk based on profiling with common genetic variants. Journal of the National Cancer Institute 107,5:
Turkman YE, Sakibia Opong A, Harris LN, et al. (2015). Biologic, demographic, and social factors affecting triple negative breast cancer outcomes. Clinical journal of oncology nursing 19,1:62-67.
RADIOTHERAPY AND IMAGING
Bartlett FR, Colgan RM, Donovan EM, et al. (2015). The UK HeartSpare Study (Stage IB): randomised comparison of a voluntary breath-hold technique and prone radiotherapy after breast conserving surgery. Radiotherapy & Oncology 114,1:66-72.
Branderhorst W, de Groot JE, Highnam R, et al. (2015). Mammographic compression--a need for mechanical standardization. European Journal of Radiology 84,4:596-602.
Brem RF, Tabar L, Duffy SW, et al. (2015). Assessing improvement in detection of breast cancer with three-dimensional automated breast US in women with dense breast tissue: the SomoInsight Study. Radiology 274,3:663-673.
Chung Y, Kim JW, Shin KH, et al. (2015). Dummy run of quality assurance program in a phase 3 randomized trial investigating the role of internal mammary lymph node irradiation in breast cancer patients: Korean Radiation Oncology Group 08-06 study. International journal of radiation oncology, biology, physics 91,2:419-426.
Jochelson MS, Lampen-Sachar K, Gibbons G, et al. (2015). Do MRI and mammography reliably identify candidates for breast conservation after neoadjuvant chemotherapy?. Annals of Surgical Oncology 22,5:1490-1495.
Ko DH, Norriss A, Harrington CR, et al. (2015). Hypofractionated radiation treatment following mastectomy in early breast cancer: The Christchurch experience. Journal of Medical Imaging & Radiation Oncology 59,2:243-247.
Leong LC, Gombos EC, Jagadeesan J, et al. (2015). MRI kinetics with volumetric analysis in correlation with hormonal receptor subtypes and histologic grade of invasive breast cancers. AJR.American Journal of Roentgenology 204,3:W348-56.
Livi L, Meattini I, Marrazzo L, et al. (2015). Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial. European journal of cancer 51,4:451-463.
Marta GN, Macedo CR, Carvalho Hde A, et al. (2015). Accelerated partial irradiation for breast cancer: systematic review and meta-analysis of 8653 women in eight randomized trials. Radiotherapy & Oncology 114,1:42-49.
McCormick B, Winter K, Hudis C, et al. (2015). RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. Journal of Clinical Oncology 33,7:709-715.
Offersen BV, Boersma LJ, Kirkove C, et al. (2015). ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer. Radiotherapy & Oncology 114,1:3-10.
Peterson D, Truong PT, Parpia S, et al. (2015). Predictors of Adverse Cosmetic Outcome in the RAPID Trial: An Exploratory Analysis. International journal of radiation oncology, biology, physics 91,5:968-976.
Verhoeven K, Weltens C, Remouchamps V, et al. (2015). Vessel based delineation guidelines for the elective lymph node regions in breast cancer radiation therapy - PROCAB guidelines. Radiotherapy & Oncology 114,1:11-16.
SUPPORTIVE CARE AND SYMPTOM MANAGEMENT
Alappattu MJ, Coronado RA, Lee D, et al. (2015). Clinical characteristics of patients with cancer referred for outpatient physical therapy. Physical Therapy 95,4:526-538.
Bower JE, Crosswell AD, Stanton AL, et al. (2015). Mindfulness meditation for younger breast cancer survivors: A randomized controlled trial. Cancer 121,8:1231-1240.
Brown JC, Kumar A, Cheville AL, et al. (2015). Association between lymphedema self-care adherence and lymphedema outcomes among women with breast cancer-related lymphedema. American Journal of Physical Medicine & Rehabilitation 94,4:288-296.
Budhrani PH, Lengacher CA, Kip K, et al. (2015). An integrative review of subjective and objective measures of sleep disturbances in breast cancer survivors. Clinical journal of oncology nursing 19,2:185-191.
Causarano N, Platt J, Baxter NN, et al. (2015). Pre-consultation educational group intervention to improve shared decision-making for postmastectomy breast reconstruction: a pilot randomized controlled trial. Supportive Care in Cancer 23,5:1365-1375.
Do J, Cho Y and Jeon J. (2015). Effects of a 4-week multimodal rehabilitation program on quality of life, cardiopulmonary function, and fatigue in breast cancer patients. Journal of Breast Cancer 18,1:87-96.
Eckhoff L, Knoop A, Jensen MB, et al. (2015). Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors. European journal of cancer 51,3:292-300.
Haddadi M, Muhammadnejad S, Sadeghi-Fazel F, et al. (2015). Systematic review of available guidelines on fertility preservation of young patients with breast cancer. Asian Pacific Journal of Cancer Prevention: Apjcp 16,3:1057-1062.
Henneghan AM and Harrison T. (2015). Complementary and alternative medicine therapies as symptom management strategies for the late effects of breast cancer treatment. Journal of Holistic Nursing 33,1:84-97.